S.L. MOROZOV^1,2, N.YU. KOVAL³, E.S. STOLYAREVICH⁴, O.R. PIRUZIEVA¹, T.V. LEPAEVA¹, T.A. NIKISHINA¹, O.V. TARASOVA², V.V. DLIN¹

 ¹Veltischev Research and Clinical Institute for Pediatrics, Moscow

²Pirogov Russian National Research Medical University, Moscow

³Tver State Medical University, Tver

⁴City Clinical Hospital No. 52 of the Moscow Health Department, Moscow City Nephrology Center, Moscow

  Contact details:

Morozov S.L. — PhD (medicine), Leading Researcher of the Department of Hereditary and Acquired Kidney Diseases named after M.S. Ignatova, Associate Professor of the Department of Hospital Therapy No. 2 of the Pediatrics Faculty

Address: 2 Taldomskaya St., Moscow, Russian Federation, 125412, tel.: +7-903-138-77-32, e-mail: mser@list.ru

 Systemic lupus erythematosus is a chronic autoimmune disease accompanied by the synthesis of autoantibodies and the deposition of complement-fixing immune complexes in damaged tissues and organs. Systemic lupus erythematosus has many clinical manifestations, with kidney damage, the so-called lupus nephritis, being one of the most dangerous. The problem of lupus nephritis is especially relevant in pediatric practice, since it is believed that in children the disease is more severe than in adults and is often associated with infant mortality. This article presents modern ideas about the pathogenesis, clinical picture, and therapeutic tactics for lupus nephritis, as well as a clinical observation of class I lupus nephritis occurring with lupus podocytopathy.

Key words: children, systemic lupus erythematosus, lupus nephritis, lupus nephritis, podocytopathy, immunosuppressive therapy.

REFERENCES

1. Fradin S. A new suture for external silicone sponge implants. Arch Ophthalmol Chic Ill, 1960, 1971, vol. 86,  pp. 58–59. DOI: 10.1001/archopht.1971.01000010060011
2. Pinheiro S.V.B., Dias R.F., Fabiano R.C.G. et al. Pediatric lupus nephritis. J Bras Nefrol Orgao of Soc Bras E Lat-Am Nefrol, 2019,  vol. 41,  pp. 252–265. DOI: 10.1590/2175-8239-JBN-2018-0097
3. Malattia C., Martini A. Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol, 2013,  vol. 27,  pp. 351–362. DOI: 10.1016/j.berh.2013.07.007
4. Mohan C., Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol, 2015,  vol. 11,  pp. 329–341. DOI: 10.1038/nrneph.2015.33
5. Somers E.C., Marder W., Cagnoli P. et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol Hoboken NJ, 2014,  vol. 66,  pp. 369–378. DOI: 10.1002/art.38238
6. Kamphuis S., Silverman E.D. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol, 2010,  vol. 6,  pp. 538–546. DOI: 10.1038/nrrheum.2010.121
7. Lewandowski L.B., Schanberg L.E., Thielman N. et al. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lupus, 2017, vol. 26,  pp. 186–194. DOI: 10.1177/0961203316660625
8. Levy D.M., Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am, 2012,  vol. 59,  pp. 345–364. DOI: 10.1016/j.pcl.2012.03.007
9. Bennett M., Brunner H.I. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am, 2013,  vol. 39,  pp. 833–853. DOI: 10.1016/j.rdc.2013.05.001
10. Hiraki L.T., Lu B., Alexander S.R. et al. End-stage renal disease due to lupus nephritis among children in the US, 1995–2006. Arthritis Rheum, 2011,  vol. 63,  pp. 1988–1997. DOI: 10.1002/art.30350
11. Flores-Mendoza G., Sansón S.P., Rodríguez-Castro S. et al. Mechanisms of Tissue Injury in Lupus Nephritis. Trends Mol Med, 2018,  vol. 24,  pp. 364–378. DOI: 10.1016/j.molmed.2018.02.003
12. Harley J.B., Alarcón-Riquelme M.E. et al. The International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet, 2008,  vol. 40,  pp. 204–210. DOI: 10.1038/ng.81
13. Muñoz L.E., Lauber K., Schiller M. et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol, 2010,  vol. 6,  pp. 280–289. DOI: 10.1038/nrrheum.2010.46
14. Arbuckle M.R., McClain M.T., Rubertone M.V. et al. Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus. N Engl J Med, 2003,  vol. 349, pp. 1526–1533. DOI: 10.1056/NEJMoa021933
15. Hanly J.G., O’Keeffe A.G., Su L. et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatol Oxf Engl, 2016,  vol. 55, pp. 252–262. DOI: 10.1093/rheumatology/kev311
16. Zabaleta-Lanz M., Vargas-Arenas R.E., Tápanes F. et al. Silent nephritis in systemic lupus erythematosus. Lupus, 2003, vol. 12, pp. 26–30. DOI: 10.1191/0961203303lu259oa
17. Fenton K., Fismen S., Hedberg A. et al. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PloS One, 2009,  vol. 4,  pp. e8474. DOI: 10.1371/journal.pone.0008474
18. Lefkowith J.B., Gilkeson G.S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum, 1996,  vol. 39,  pp. 894–903. DOI: 10.1002/art.1780390605
19. Bruschi M., Galetti M., Sinico R.A. et al. Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. J Am Soc Nephrol JASN, 2015, vol. 26,  pp. 1905–1924. DOI: 10.1681/ASN.2014050493
20. Mayadas T.N., Rosetti F., Ernandez T. et al. Neutrophils: game changers in glomerulonephritis? Trends Mol Med, 2010,  vol. 16,  pp. 368–378. DOI: 10.1016/j.molmed.2010.06.002
21. Lintner K.E., Wu Y.L., Yang Y. et al. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol, 2016,  vol. 7,  p. 36. DOI: 10.3389/fimmu.2016.00036
22. Mittal M., Siddiqui M.R., Tran K. et al. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal, 2014,  vol. 20,  pp. 1126–1267. DOI: 10.1089/ars.2012.5149
23. Mok C-C. Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health, 2012,  vol. 213. DOI: 10.2147/IJWH.S28034
24. Marto N. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis., 2004, vol. 64,  pp. 444–448. DOI: 10.1136/ard.2004.024943
25. Bajema I.M., Wilhelmus S., Alpers C.E. et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int, 2018,  vol. 93,  pp. 789–796. DOI: 10.1016/j.kint.2017.11.023
26. Bankole A.A., Nwaonu J.N. The Shifting Landscape of Lupus Nephritis Management: A Review. Cureus Published Online First: 5 January 2022. DOI: 10.7759/cureus.20950
27. De Rosa M., Azzato F., Toblli J.E. et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int, 2018,  vol. 94,  pp. 788–794. DOI: 10.1016/j.kint.2018.05.021
28. Alsuwaida A., Husain S., Alghonaim M. et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc — Eur Ren Assoc, 2012,  vol. 27,  pp. 1472–1478. DOI: 10.1093/ndt/gfr517
29. Barron K.S., Person D.A., Brewer E.J. et al. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr, 1982,  vol. 101,  pp. 137–141. DOI: 10.1016/S0022-3476(82)80203-5
30. Mejía-Vilet J.M., Ayoub I. The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. Front Med, 2021,  vol. 8. DOI: 10.3389/fmed.2021.622225
31. Ginzler E.M., Dooley M.A., Aranow C. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med, 2005,  vol. 353,  pp. 2219–2228. DOI: 10.1056/NEJMoa043731
32. Walsh M., James M., Jayne D. et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol, 2007,  vol. 2, pp. 968–975. DOI: 10.2215/CJN.01200307